Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

(2020) Marie-Helene Delfau-Larue et al.   Blood Advances

RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

(2019) M. Federico et al.   HEMATOLOGICAL ONCOLOGY

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

(2019) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

(2019) Monika Brüggemann et al.   LEUKEMIA

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

(2019) Christiane Pott et al.   LEUKEMIA

Precision Medicine in Lymphoma by Innovative Instrumental Platforms

(2019) Antonello Di Paolo et al.   Frontiers in Oncology

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

(2018) Mazyar Shadman et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

(2018) Wolfgang Hiddemann et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

(2018) Stefano Luminari et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

(2018) Judith Trotman et al.   LANCET ONCOLOGY

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

(2016) S. F. Barrington et al.   BLOOD

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

(2015) S. Luminari et al.   HAEMATOLOGICA

Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma

(2015) Michael Herold et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

(2015) S. Luminari et al.   HAEMATOLOGICA

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

(2014) S. Luminari et al.   ANNALS OF ONCOLOGY

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

(2014) S. Galimberti et al.   CLINICAL CANCER RESEARCH

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

(2014) Judith Trotman et al.   Lancet Haematology

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

(2013) Simone Ferrero et al.   ANNALS OF HEMATOLOGY

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

(2013) S. Luminari et al.   ANNALS OF ONCOLOGY

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

(2013) M. Ladetto et al.   BLOOD

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

(2009) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY